2024-11-04 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison:**

Eli Lilly and Co. (LLY) is a pharmaceutical company developing and manufacturing pharmaceutical products. LLY's cumulative return is 774.98%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 131.78%. The difference in returns is 643.2%, which places LLY in the 80.22% percentile of its historical performance against VOO.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | 19.1% | 13.8% | 18.8% | 0.0 |
| 2016 | -15.9% | 19.2% | -25.5% | -1.7 |
| 2017 | 13.9% | 10.1% | -5.5% | 0.7 |
| 2018 | 40.7% | 14.7% | 51.3% | -3.8 |
| 2019 | 16.4% | 17.2% | -14.6% | 0.5 |
| 2020 | 42.1% | 22.1% | 21.8% | 2.1 |
| 2021 | 122.8% | 18.6% | 83.6% | 3.1 |
| 2022 | 89.9% | 13.5% | 135.4% | -2.0 |
| 2023 | 222.9% | 14.7% | 188.3% | 6.5 |
| 2024 | 223.1% | 18.7% | 189.6% | 6.7 |

LLY has demonstrated significant alpha, outperforming the market consistently, especially in recent years. The beta indicates that LLY is more volatile than the market, but its outperformance and consistent alpha suggest a strong long-term investment potential.

**2. Recent Price Movement:**

* **Closing Price:** 818.93 
* **5-Day Moving Average:** 858.93
* **20-Day Moving Average:** 898.31
* **60-Day Moving Average:** 913.13

The current price is below all moving averages, suggesting a downward trend.

**3. Technical Indicators:**

* **RSI:** 13.25 (Oversold)
* **PPO:** -1.08 (Sell Signal)
* **20-Day Relative Divergence:** -9.05 (Negative, Short-Term Downward Trend)
* **Expected Return:** 97.64% (Potential for exceeding S&P 500 returns over the next two years)

The technical indicators suggest that the stock is currently oversold, and a potential rebound could be on the horizon. However, the negative short-term trend and sell signal from the PPO warrant caution.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | $11.44 B |
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2024-10-30 | -0.06 | $9.50 B |

The most recent earnings (2024-10-30) beat analysts' expectations, with EPS of 1.08 exceeding the estimate of 0.92. Revenue also surpassed expectations, indicating strong performance. This, coupled with the previous quarter's strong earnings, suggests a positive outlook for LLY.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |

LLY consistently demonstrates high profit margins, indicating strong profitability and efficient operations. Revenue growth has been consistent, indicating a healthy expansion strategy.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

While ROE has been fluctuating, it generally shows positive trends, indicating good returns on shareholders' investments. 

**6. News and Recent Issues:**

* **Recent Earnings News:** The recent earnings release on October 30th, 2024, showed a significant beat on both EPS and revenue, indicating strong performance and positive future prospects.
* **Market Outlook:** According to FINBOLD, LLY is considered a strong buy with a consensus price target of $950. Analysts are bullish on LLY's future performance based on its strong earnings, pipeline, and market dominance.

**7. Overall Analysis:**

LLY is a strong company with a robust track record of outperforming the market. Its consistent earnings growth, strong financials, and optimistic market outlook suggest potential for further growth. Although currently oversold and in a short-term downward trend, the technical indicators suggest potential for a rebound. The high expected return over the next two years makes it a good candidate for long-term investment.

**8. Conclusion:**

Despite the recent downward price movement, Eli Lilly and Co. (LLY) remains a strong investment opportunity for long-term investors. Its consistent outperformance, strong financial position, and positive market outlook suggest a positive outlook for future growth. While the current technical indicators warrant caution, the stock's high expected return and strong fundamentals make it a compelling buy for investors seeking a long-term growth opportunity.